Does Thromboxane A2 Inhibitors Interact with Verteporfin For Injection?
Thromboxane A2 Inhibitors and Verteporfin For Injection have a moderate drug interaction according to U.S. FDA drug labeling data. Drugs that decrease clotting, vasoconstriction or platelet aggregation could decrease the efficacy of VISUDYNE therapy. The mechanism involves decreased clotting and platelet aggregation. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This information is based on official FDA drug labeling sourced from OpenFDA and the NIH National Library of Medicine.
- Severity
- Moderate
- Verteporfin For Injection Class
- Photoenhancer
- Management
- Monitor for effects
- Data Source
- U.S. FDA via OpenFDA
How This Interaction Works
The interaction between Thromboxane A2 Inhibitors and Verteporfin For Injection occurs because decreased clotting and platelet aggregation. Clinically, this means drugs that decrease clotting, vasoconstriction or platelet aggregation could decrease the efficacy of visudyne therapy. This is classified as a moderate interaction. While it may not require stopping either medication, your healthcare provider should be aware you are taking both so they can monitor for potential effects and adjust treatment if necessary.
What To Tell Your Doctor or Pharmacist
If you are taking Thromboxane A2 Inhibitors and your doctor is considering prescribing Verteporfin For Injection (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider